Axithra
9 known investors
Find your way into Axithra
Axithra, a spin-off from Ghent University's Photonics Research Group and imec, develops an optics- and photonics-based platform for therapeutic drug monitoring that measures and monitors drug concentrations in blood at the point of care. Its lead application targets personalizing β-lactam antibiotic treatment for patients in intensive care units.
Investors · 9
imec.xpandLeuven · $270K – $5.4M
Kurma PartnersParis · $162K – $10.8M
Qbic FundSt-Denijs-Westrem
White FundLiège · $2.2M – $5.4M
Wallonie EntreprendrereportedLiège
Also in the syndicate · 4
Hamamatsu PhotonicsNoshaqQbicWerfen Diagnostics
Funding
SEC filings, press & company announcements- Undisclosed amountseed roundSep 2023
imec.xpand (lead), Kurma Partners (lead), Hamamatsu Photonics, Noshaq, Qbic, Wallonie Entreprendre, Werfen Diagnostics, White Fund
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Axithra do?
- Axithra, a spin-off from Ghent University's Photonics Research Group and imec, develops an optics- and photonics-based platform for therapeutic drug monitoring that measures and monitors drug concentrations in blood at the point of care. Its lead application targets personalizing β-lactam antibiotic treatment for patients in intensive care units.
- Who are Axithra's investors?
- Axithra's investors include imec.xpand, Kurma Partners, Qbic Fund, White Fund, Wallonie Entreprendre.